Home » Stocks » PRFX

PainReform Ltd. (PRFX)

Stock Price: $2.82 USD -0.01 (-0.35%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $3.06 +0.24 (8.51%) Jun 11, 7:38 PM
Market Cap 28.38M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 10.06M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $2.82
Previous Close $2.83
Change ($) -0.01
Change (%) -0.35%
Day's Open 2.90
Day's Range 2.80 - 2.94
Day's Volume 98,436
52-Week Range 2.18 - 7.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Reports continued progress towards start of Phase 3 trials Reports continued progress towards start of Phase 3 trials

4 weeks ago - GlobeNewsWire

HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of est...

2 months ago - GlobeNewsWire

HERZLIYA, Israel, March 11, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of est...

3 months ago - GlobeNewsWire

HERZLIYA, Israel, March 08, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of est...

3 months ago - GlobeNewsWire

HERZLIYA, Israel, Jan. 07, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of esta...

5 months ago - GlobeNewsWire

HERZLIYA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of esta...

5 months ago - GlobeNewsWire

About PRFX

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporat... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Sep 1, 2020
Stock Exchange
NASDAQ
Ticker Symbol
PRFX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for PainReform stock is "Buy" and the 12-month stock price forecast is 10.00.

Price Target
$10.00
Analyst Consensus: Buy